Role of transforming growth factor beta3 in lymphatic metastasis in breast cancer.
Authors
Li, ChenggangWang, Ji Min
Wilson, Philip B
Kumar, Patricia
Levine, Edward
Hunter, Robin D
Kumar, Shant
Affiliation
Department of Pathology, Medical School, University of Manchester, UK.Issue Date
1998-10-23
Metadata
Show full item recordAbstract
Transforming growth factor-betas (TGFbetas) play a prominent role in tumour growth and metastasis by enhancing angiogenesis and suppressing immune surveillance. Despite the increased interest in the effect of TGFbetas on tumour progression, little is known about the importance of TGFbeta3 and its receptor CD105 in breast cancer. In the present study, we measured the plasma levels of TGFbeta3, CD105-TGFbeta3 complexes and TGFbeta1 in 80 patients with untreated early-stage breast cancer using an enhanced chemiluminescence ELISA method. Of the 80 patients, 14 were histologically confirmed as having axillary lymph node metastases, while the remainder had no evidence of lymph node involvement. The results showed that levels of both TGFbeta3 and CD105-TGFbeta3 complex were significantly elevated in patients with positive lymph nodes compared to those without node metastasis. Furthermore, the levels of both TGFbeta3 and CD105-TGFbeta3 complex correlated with lymph node status. The only patient who died of the disease had very high plasma levels of TGFbeta3 and CD105-TGFbeta3 complex and positive lymph nodes; this patient developed lung metastases within 2 years of diagnosis. No significant correlation was seen between either TGFbeta3 or CD105-TGFbeta3 complex levels and tumour stage, size or histological grade. Plasma TGFbeta1 levels were not correlated with node metastasis, tumour stage, grade or size. Our data suggest that plasma levels of TGFbeta3 and CD105-TGFbeta3 complex may be of prognostic value in the early detection of metastasis of breast cancer.Citation
Role of transforming growth factor beta3 in lymphatic metastasis in breast cancer. 1998, 79 (5):455-9 Int. J. CancerJournal
International Journal of Cancer.DOI
10.1002/(SICI)1097-0215(19981023)79:5<449::AID-IJC1>3.0.CO;2-0PubMed ID
9761112Type
ArticleLanguage
enISSN
0020-7136ae974a485f413a2113503eed53cd6c53
10.1002/(SICI)1097-0215(19981023)79:5<449::AID-IJC1>3.0.CO;2-0
Scopus Count
Collections
Related articles
- Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer.
- Authors: Li C, Guo B, Wilson PB, Stewart A, Byrne G, Bundred N, Kumar S
- Issue date: 2000 Mar 20
- Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis.
- Authors: Li C, Gardy R, Seon BK, Duff SE, Abdalla S, Renehan A, O'Dwyer ST, Haboubi N, Kumar S
- Issue date: 2003 May 6
- The significance of CD105, TGFbeta and CD105/TGFbeta complexes in coronary artery disease.
- Authors: Li CG, Bethell H, Wilson PB, Bhatnagar D, Walker MG, Kumar S
- Issue date: 2000 Sep
- Angiogenesis in breast cancer: the role of transforming growth factor beta and CD105.
- Authors: Li C, Guo B, Bernabeu C, Kumar S
- Issue date: 2001 Feb 15
- TGF-beta1 levels in pre-treatment plasma identify breast cancer patients at risk of developing post-radiotherapy fibrosis.
- Authors: Li C, Wilson PB, Levine E, Barber J, Stewart AL, Kumar S
- Issue date: 1999 Apr 20